The present invention relates to a buffer composition having a pH of from 6.7 to 7.9 at a temperature of 37° C., for use in the treatment, prophylactic treatment or amelioration of an airborne viral infection, or for use in reducing viral replication in a subject infected with an airborne virus or exposed to an airborne virus capable of causing an airborne viral infection in the subject. The buffer composition may comprise an N- substituted aminosulphonic acid. The present invention also relates to a method of preparing the buffer composition, and to a concentrate of the buffer composition. The buffer composition can be used in a method of treatment, prophylactic treatment or amelioration of an airborne viral infection in a subject, and a method of reducing viral replication in a subject infected with an airborne virus or exposed to an airborne virus capable of causing an airborne viral infection in the subject. Airborne viruses include RNA viruses, such as coronaviruses, such as MERS-CoV, SARS-CoV, and SARS-CoV-2. The buffer composition can be administered by nasal spray, inhaler or nebulizer, or in the form of a cream, gel or emulsion, and the invention therefore also relates to a nasal spray, inhaler, nebulizer, cream, gel or emulsion comprising the buffer composition. The buffer composition can also be applied to a mask or other face covering thereby reducing the risk of viral infection with an airborne virus, and the invention therefore also relates to a spray comprising the buffer composition. The buffer composition can also be used in a receptacle through which an oxygen-containing gas is bubbled prior to inhalation by a subject, and the invention therefore also relates to a receptacle containing the buffer composition.

The present invention relates to a stable pharmaceutical formulation comprising omeprazole, its enantiomer, or its pharmaceutically acceptable salt, and sodium bicarbonate, and a method for preparing the same. Specifically, the present invention provides a stable formulation by preventing omeprazole, its enantiomer, or its pharmaceutically acceptable salt, from coming in direct contact with sodium bicarbonate, to reduce the production of impurities.

The present invention relates to a stable pharmaceutical formulation comprising omeprazole, its enantiomer, or its pharmaceutically acceptable salt, and sodium bicarbonate, and a method for preparing the same. Specifically, the present invention provides a stable formulation by preventing omeprazole, its enantiomer, or its pharmaceutically acceptable salt, from coming in direct contact with sodium bicarbonate, to reduce the production of impurities.

The disclosure provides for pharmaceutical compositions comprising an alginate salt, such as sodium alginate. The disclosure further provides for processes and methods for making pharmaceutical compositions. In yet a further aspect, the disclosure provides for methods of utilizing a pharmaceutical composition for treatment of acid reflux diseases. In another aspect, the disclosure provides for formulations suitable for oral use in dosage forms of capsules and dry powders.

The disclosure provides for pharmaceutical compositions comprising an alginate salt, such as sodium alginate. The disclosure further provides for processes and methods for making pharmaceutical compositions. In yet a further aspect, the disclosure provides for methods of utilizing a pharmaceutical composition for treatment of acid reflux diseases. In another aspect, the disclosure provides for formulations suitable for oral use in dosage forms of capsules and dry powders.

A surface-reacted calcium carbonate is described. In embodiments, the surface-reacted calcium carbonate is obtained by a process comprising treating a calcium carbonate-comprising material with at least one H.sub.3O.sup.+ ion donor, carbon dioxide, and at least one water-soluble metal cation source in an aqueous medium to form an aqueous suspension of surface-reacted calcium carbonate.

The present disclosure provides chewable tablets comprising (i) a compressed core including a bioactive molecule; (ii) a protective layer over said compressed core, and (iii) one or more soft-coating layers over said protective layer, each soft coating layer comprises gum base powder; wherein the protective layer comprises water-insoluble cellulose based polymers, preferably ethyl cellulose based polymer.

The present disclosure provides chewable tablets comprising (i) a compressed core including a bioactive molecule; (ii) a protective layer over said compressed core, and (iii) one or more soft-coating layers over said protective layer, each soft coating layer comprises gum base powder; wherein the protective layer comprises water-insoluble cellulose based polymers, preferably ethyl cellulose based polymer.

The present embodiments provide systems and medical formulations suitable for delivering therapeutic powders to a target site. In one embodiment, the system comprises a delivery device, a first powder being formed of particles of a first material, and a second powder being formed of particles of a second material, wherein the second material is different than the first material. At least some of the particles of the first powder and the second powder are bound together to form bonded particles. The bonded particles are simultaneously delivered to the target site by the delivery device. In one embodiment, a medical formulation may comprise carbomer present in a range between about 60-80% by weight of the formulation, bentonite present in a range of between about 5-15% by weight of the formulation, and calcium carbonate present in a range of between about 10-30% by weight of the formulation.

The present embodiments provide systems and medical formulations suitable for delivering therapeutic powders to a target site. In one embodiment, the system comprises a delivery device, a first powder being formed of particles of a first material, and a second powder being formed of particles of a second material, wherein the second material is different than the first material. At least some of the particles of the first powder and the second powder are bound together to form bonded particles. The bonded particles are simultaneously delivered to the target site by the delivery device. In one embodiment, a medical formulation may comprise carbomer present in a range between about 60-80% by weight of the formulation, bentonite present in a range of between about 5-15% by weight of the formulation, and calcium carbonate present in a range of between about 10-30% by weight of the formulation.